258 related articles for article (PubMed ID: 7038650)
21. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Holland JF; Ohnuma T
Cancer Treat Rep; 1981; 65 Suppl 4():123-30. PubMed ID: 7049376
[TBL] [Abstract][Full Text] [Related]
22. Is L-asparaginase an antiblastic agent?
Astaldi G
Haematologia (Budap); 1972; 6(4):433-46. PubMed ID: 4274316
[No Abstract] [Full Text] [Related]
23. Establishment of asparaginase- and guinea pig complement-resistant subline of murine lymphoblastic leukemia L5178y cells.
Yang TJ; Gawlak S
Oncology; 1984; 41(6):446-51. PubMed ID: 6390288
[TBL] [Abstract][Full Text] [Related]
24. [Results of an experimental study of the antitumor activity of 1-asparaginase from E. coli and Erw. carotovora].
Terent'eva TG; Sokolov AB; Navashin SM
Antibiotiki; 1977 Jan; 22(1):78-81. PubMed ID: 320935
[TBL] [Abstract][Full Text] [Related]
25. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience with L-asparaginase.
Carbone PP; Haskell CM; Leventhal BG; Block JB; Selawry OS
Recent Results Cancer Res; 1970; 33():236-43. PubMed ID: 4949163
[No Abstract] [Full Text] [Related]
27. Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice.
Vadlamudi S; Krishna B; Reddy VV; Goldin A
Cancer Res; 1973 Sep; 33(9):2014-9. PubMed ID: 4725366
[No Abstract] [Full Text] [Related]
28. L-asparaginase bound to collagen membrane in an extracorporeal device: an intermittent antitumor enzyme therapy delivery system.
Joyeuse R; Kim HC; Saidi P; McBride KJ; Jefferies SR; Bernath FR
Surg Forum; 1976; 27(62):115-6. PubMed ID: 1019820
[No Abstract] [Full Text] [Related]
29. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
Avery TL; Roberts D
Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
[No Abstract] [Full Text] [Related]
30. Suppressive effect of indazole adenine dinucleotides on proliferation of normal and malignant cells.
Tono-Oka S; Tone Y; Azuma I
Int J Vitam Nutr Res; 1986; 56(1):119-24. PubMed ID: 2872178
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of azaserine and DON.
Burchenal JH
Cancer Treat Rep; 1979 Jun; 63(6):1031-2. PubMed ID: 466642
[No Abstract] [Full Text] [Related]
32. Favorable remission induction rate with twice weekly doses of L-asparaginase.
Jaffe N; Traggis D; Das L; Frauenberger G; Hann HW; Kim BS; Bishop Y
Cancer Res; 1973 Jan; 33(1):1-4. PubMed ID: 4565907
[No Abstract] [Full Text] [Related]
33. Factors influencing the therapeutic activity of L-asparaginase (NSC 109229) in leukemic (L5178Y) mice.
Vadlamudi S; Padarathsingh M; Waravdekar VS; Goldin A
Cancer Res; 1970 May; 30(5):1467-72. PubMed ID: 5426950
[No Abstract] [Full Text] [Related]
34. Use of a human lymphoid cell line to evaluate interactions between prednisolone and other chemotherapeutic agents.
Norman MR; Harmon JM; Thompson EB
Cancer Res; 1978 Nov; 38(11 Pt 2):4273-8. PubMed ID: 279403
[No Abstract] [Full Text] [Related]
35. Differences between 5-fluoro-2'-deoxyuridine and 5-fluorouridine in their cytotoxic effect on growth of murine lymphoma L5178Y cells in in vivo and in vitro systems.
Kanzawa F; Hoshi A; Kuretani K
Eur J Cancer (1965); 1980 Aug; 16(8):1087-92. PubMed ID: 6449368
[No Abstract] [Full Text] [Related]
36. In vitro test for sensitivity of leukemic cells to L-asparaginase.
Schrek R; Dolowy WC
Cancer Res; 1971 May; 31(5):523-6. PubMed ID: 4932205
[No Abstract] [Full Text] [Related]
37. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia.
Savoca KV; Davis FF; van Es T; McCoy JR; Palczuk NC
Cancer Biochem Biophys; 1984 Sep; 7(3):261-8. PubMed ID: 6488153
[TBL] [Abstract][Full Text] [Related]
38. Severe hepatotoxicity from Escherichia coli L-asparaginase.
Jenkins R; Perlin E
J Natl Med Assoc; 1987 Jul; 79(7):775, 779. PubMed ID: 3305969
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity and other biologic properties of L-asparaginase (NSC-109229)-a review.
Adamson RH; Fabro S
Cancer Chemother Rep; 1968 Oct; 52(6):617-26. PubMed ID: 4895425
[No Abstract] [Full Text] [Related]
40. Asparaginase: molecular and enzymic requirements for use as an antileukaemia agent.
Wade HE
J Gen Microbiol; 1971 Mar; 65(3):x-xi. PubMed ID: 4997395
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
